EC Number   |
Substrates |
Organism |
Products  |
Reversibility |
|---|
    3.5.4.5 | 2',2'-difluorodeoxycytidine + H2O |
gemcitabine, antimetabolite of deoxycytidine, active against solid tumors and leukemic cell lines, deamination by the enzyme results in loss of pharmacologic activity |
Homo sapiens |
2',2'-difluorodeoxyuridine + NH3 |
- |
? |
| 3.5.4.5 | 2',2'-difluorodeoxycytidine + H2O |
deamination of the deoxynucleoside analogue gemcitabine (dFdC) to difluorodeoxyuridine (dFdU), difluorodeoxyuridine used as radiosensitizer in gene therapy |
Homo sapiens |
2',2'-difluorodeoxyuridine + NH3 |
- |
? |
| 3.5.4.5 | 2',3'-dideoxycytidine + H2O |
- |
Homo sapiens |
2',3'-dideoxyuridinel + NH3 |
- |
? |
| 3.5.4.5 | 2',3'-dideoxycytidine + H2O |
selective inhibitor of HIV reverse transcriptase |
Arabidopsis thaliana |
2',3'-dideoxyuridinel + NH3 |
- |
? |
| 3.5.4.5 | 2',5'-anhydroarabinosylcytosine + H2O |
- |
Mus musculus |
2',5'-anhydroarabinosyluracil + NH3 |
- |
? |
| 3.5.4.5 | 2',5'-anhydroarabinosylcytosine + H2O |
- |
Mus musculus BALB/c |
2',5'-anhydroarabinosyluracil + NH3 |
- |
? |
| 3.5.4.5 | gemcitabine + H2O |
CDA is the major enzyme involved in gemcitabine inactivation, a cytotoxic drug commonly used in the treatment of pancreas and non-small cell lung cancer |
Homo sapiens |
2'-deoxy-2',2'-difluorouridine |
- |
? |
| 3.5.4.5 | 2'-deoxycytidine + H2O |
- |
Mus musculus |
2'-deoxyuridine + NH3 |
- |
? |
| 3.5.4.5 | 2'-deoxycytidine + H2O |
- |
Escherichia coli |
2'-deoxyuridine + NH3 |
- |
? |
| 3.5.4.5 | 2'-deoxycytidine + H2O |
- |
Homo sapiens |
2'-deoxyuridine + NH3 |
- |
? |
